The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to Becton, Dickinson and Company’s (BD) new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV).
Designed for use on the BD MAX molecular diagnostic system, the test uses a single nasal or nasopharyngeal swab sample to detect and differentiate whether a patient has Covid-19, the flu, RSV or a combination of the three.
The Respiratory Viral Panel for BD MAX System is an RT-PCR assay, which identifies and differentiates the nucleic acid of SARS-CoV-2, flu A, flu B and RSV within two hours for the first result.
Designed to help combat illness in the current and future respiratory virus seasons, the test is claimed to enable clinicians to rapidly implement the right treatment plan.
Furthermore, the co-testing process will help enhance testing capacity as well as speed time to diagnosis during the busy flu/RSV season, stated BD.
BD molecular diagnostics vice-president Nikos Pavlidis said: “While fears of a ‘tripledemic’ this respiratory season have largely diminished, accurately differentiating influenza and RSV from Covid-19 and providing appropriate treatment remains a challenge for our customers.
“This diagnostic test provides the ability to identify multiple pathogens using a single sample and can quickly pinpoint the causative virus or viruses and enable clinicians to administer appropriate treatment early in the course of infection.”
The company secured the CE mark for the BD Respiratory Viral Panel assay for BD MAX System last May.
BD also introduced the new third-generation BD Kiestra Total Lab Automation System for microbiology laboratories last month.